Uncertainties Surrounding the EU Joint Clinical Assessment: What do Biotechs Need to Monitor

The European Joint Clinical Assessment (JCA) represents a significant evolution in the market access process for pharma and biotech companies seeking reimbursement in EU markets. However, with the implementation of the EU Health Technology Assessment (HTA) Regulation and JCA just four months away, uncertainties remain regarding the actual PICO creation, some process details, and adoption of reports at Member State level. In this short clip, we list the critical areas of uncertainty. In the next part of this series, we will offer strategies to prepare for and navigate these complexities.

Now is the time to prepare for the impact of the JCA on market entry. 

Contact Apersy for expert guidance on how to successfully manage these challenges and optimize your market access readiness for Europe.